ceftibuten ceftibuten ceftibuten is a third-generation cephalosporin antibiotic. it is an orally administered agent, with two dosage forms, capsule or oral suspension. it is marketed by pernix therapeutics under the trade name cedax. ceftibutenclinical datatrade namescedaxahfs/drugs.commonographmedlineplusa698023atc codej01dd14 (who) identifiers iupac name (6r,7r)-7-(amino)-8-oxo-5-thia-1-azabicyclooct-2-ene-2-carboxylic acid cas number97519-39-6 ypubchem cid5282242drugbankdb01415 ychemspider4445419 yuniiiw71n46b4ykeggd00922 ychebichebi:3510 ychemblchembl1605 ycomptox dashboard (epa)dtxsid4045925 echa infocard100.238.211 chemical and physical dataformulac15h14n4o6s2molar mass410.42 g·mol−13d model (jsmol)interactive image smiles o=c2n1/c(=c\cs12nc(=o)c(=c/cc(=o)o)\c3nc(sc3)n)c(=o)o inchi inchi=1s/c15h14n4o6s2/c16-15-17-7(5-27-15)6(1-2-9(20)21)11(22)18-10-12(23)19-8(14(24)25)3-4-26-13(10)19/h1,3,5,10,13h,2,4h2,(h2,16,17)(h,18,22)(h,20,21)(h,24,25)/b6-1-/t10-,13-/m1/s1 ykey:unjfkxssgbwrbz-bjcipqkhsa-n y (verify) medical uses main article: cephalosporin ceftibuten is used to treat acute bacterial exacerbations of chronic bronchitis (abecb), acute bacterial otitis media, pharyngitis, and tonsilitis. it is also indicated for pneumonia, infections of the urinary tract, enteritis, and gastroenteritis. adverse effects in 3,000 patients, ceftibuten was well tolerated. the most frequent reactions were gastrointestinal and nausea. susceptibility ceftibuten is active against haemophilus influenzae, moraxella catarrhalis, escherichia coli, klebsiella pneumoniae, k. oxytoca, proteus vulgaris, p. mirabilis, p. providence, salmonella sp., shigella sp., enterobacter sp., and streptococcus sp. the following represents minimum inhibitory concentration (mic) susceptibility data for a few clinically significant microorganisms: haemophilus influenzae: 0.015–1.0 μg/ml moraxella catarrhalis: 0.5–4.0 μg/ml streptococcus pneumoniae: 0.5–256 μg/ml